{"uri": "eng-9428973", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 100, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Priority_review", "type": "wiki", "score": 95, "label": {"eng": "Priority review"}}, {"uri": "http://en.wikipedia.org/wiki/New_drug_application", "type": "wiki", "score": 79, "label": {"eng": "New drug application"}}, {"uri": "http://en.wikipedia.org/wiki/Prescription_Drug_User_Fee_Act", "type": "wiki", "score": 75, "label": {"eng": "Prescription Drug User Fee Act"}}, {"uri": "http://en.wikipedia.org/wiki/Oncology", "type": "wiki", "score": 75, "label": {"eng": "Oncology"}}, {"uri": "http://en.wikipedia.org/wiki/Medication", "type": "wiki", "score": 65, "label": {"eng": "Medication"}}, {"uri": "http://en.wikipedia.org/wiki/Acute_leukemia", "type": "wiki", "score": 65, "label": {"eng": "Acute leukemia"}}, {"uri": "http://en.wikipedia.org/wiki/Enzyme_inhibitor", "type": "wiki", "score": 55, "label": {"eng": "Enzyme inhibitor"}}, {"uri": "http://en.wikipedia.org/wiki/Disease", "type": "wiki", "score": 55, "label": {"eng": "Disease"}}, {"uri": "http://en.wikipedia.org/wiki/Pediatrics", "type": "wiki", "score": 55, "label": {"eng": "Pediatrics"}}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 50, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Relapse", "type": "wiki", "score": 45, "label": {"eng": "Relapse"}}, {"uri": "http://en.wikipedia.org/wiki/Cancer", "type": "wiki", "score": 41, "label": {"eng": "Cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_endpoint", "type": "wiki", "score": 40, "label": {"eng": "Clinical endpoint"}}, {"uri": "http://en.wikipedia.org/wiki/Cure", "type": "wiki", "score": 39, "label": {"eng": "Cure"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 35, "label": {"eng": "Chief executive officer"}}], "eventDate": "2024-03-26", "totalArticleCount": 5, "title": {"eng": "FDA grants priority review to Syndax's leukemia drug By Investing.com"}, "summary": {"eng": "WALTHAM, Mass. - Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company, announced today that its New Drug Application (NDA) for revumenib has been granted Priority Review by the U.S. Food and Drug Administration (FDA). Revumenib is aimed at treating adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia.\n\nThe FDA's decision to expedite the review process comes with a Prescription Drug User Fee Act (PDUFA) target action date set for Sept"}, "location": null, "categories": [{"uri": "dmoz/Health/Specific_Substances/Tobacco", "label": "dmoz/Health/Specific Substances/Tobacco", "wgt": 100}, {"uri": "dmoz/Health/Teen_Health/Drugs_and_Alcohol", "label": "dmoz/Health/Teen Health/Drugs and Alcohol", "wgt": 80}, {"uri": "dmoz/Health/Men's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Men's Health/Conditions and Diseases", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 86}], "articleCounts": {"eng": 5}, "sentiment": 0.2156862745098038, "wgt": 449107200, "relevance": 1}